C
Clarity Pharmaceuticals Ltd
ASX:CU6
Clarity Pharmaceuticals Ltd
ASX:CU6
Price:
3.33
AUD
-3.2%
Market Closed
Market Cap:
AU$1.2B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
AU |
|
Beijing YJK Building Software Co Ltd
SZSE:300935
|
CN |
|
Huhtamaki India Ltd
NSE:HUHTAMAKI
|
IN |
|
Regis Resources Ltd
ASX:RRL
|
AU |
|
G
|
Garmin Ltd
NYSE:GRMN
|
CH |
|
S
|
Stille AB
STO:STIL
|
SE |
Cash Flow Statement
Cash Flow Statement
Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd
Currency: AUD
| Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||
| Stock-Based Compensation |
1
|
2
|
4
|
6
|
6
|
0
|
|
| Cash Taxes Paid |
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
|
| Change in Working Capital |
8
|
9
|
12
|
13
|
16
|
18
|
|
| Cash from Operating Activities |
(28)
N/A
|
(38)
-37%
|
(43)
-15%
|
(47)
-8%
|
(55)
-17%
|
(72)
-32%
|
|
| Investing Cash Flow | |||||||
| Capital Expenditures |
(0)
|
(0)
|
(1)
|
(0)
|
(0)
|
(0)
|
|
| Other Items |
3
|
3
|
(55)
|
(93)
|
52
|
(48)
|
|
| Cash from Investing Activities |
3
N/A
|
3
-14%
|
(55)
N/A
|
(94)
-69%
|
52
N/A
|
(48)
N/A
|
|
| Financing Cash Flow | |||||||
| Net Issuance of Common Stock |
0
|
0
|
122
|
124
|
2
|
204
|
|
| Other |
(0)
|
(0)
|
(7)
|
(7)
|
(0)
|
(11)
|
|
| Cash from Financing Activities |
0
N/A
|
0
+6%
|
115
+46 945%
|
117
+1%
|
2
-98%
|
193
+8 648%
|
|
| Change in Cash | |||||||
| Effect of Foreign Exchange Rates |
(0)
|
(0)
|
0
|
3
|
0
|
(6)
|
|
| Net Change in Cash |
(24)
N/A
|
(35)
-44%
|
17
N/A
|
(20)
N/A
|
(0)
+99%
|
67
N/A
|
|
| Free Cash Flow | |||||||
| Free Cash Flow |
(28)
N/A
|
(38)
-38%
|
(44)
-15%
|
(47)
-7%
|
(55)
-17%
|
(73)
-32%
|
|
Switch to:
Switch to:
See Also
Discover More
